BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $94.48 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 819,968 shares of the company's stock after buying an additional 37,098 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.81% of Neurocrine Biosciences worth $94,478,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $28,000. Innealta Capital LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at $30,000. New Covenant Trust Company N.A. bought a new stake in Neurocrine Biosciences during the 1st quarter worth about $32,000. EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $35,000. Finally, Plato Investment Management Ltd bought a new position in shares of Neurocrine Biosciences in the 1st quarter valued at about $41,000. Institutional investors and hedge funds own 92.59% of the company's stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $123.29 on Thursday. The company has a market capitalization of $12.48 billion, a P/E ratio of 33.05 and a beta of 0.35. The business's 50 day simple moving average is $118.44 and its 200 day simple moving average is $132.24. Neurocrine Biosciences, Inc. has a 1 year low of $108.63 and a 1 year high of $157.98.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NBIX. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Jefferies Financial Group increased their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a report on Monday, August 19th. Royal Bank of Canada decreased their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research note on Friday, October 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Finally, Oppenheimer lifted their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an "outperform" rating in a research report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences has an average rating of "Moderate Buy" and an average price target of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.